Quantitative and Qualitative Immune Reconstitution Analysis in an Adolescent Patient with Refractory Primary Mediastinal Large B Cell Lymphoma after Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy
Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Sajad Khazal(The University of Texas MD Anderson Cancer Center), Priti Tewari(The University of Texas MD Anderson Cancer Center), Kris M. Mahadeo(Duke University), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Dristhi Ragoonanan(The University of Texas MD Anderson Cancer Center), Demetrios Petropoulos(The University of Texas MD Anderson Cancer Center), César Núñez(Universidad de Medellín)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782